Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TYMP | P19971 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.36 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.36 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.36 |
| ▸ | GSK3A | P49840 | 1/20 | 0.35 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4328091 | 1.00 | LMNA (0.44) | LMNATYMPABCB1STING1ALDH1A1 | |
| SCHEMBL4260807 | 1.00 | LMNA (0.44) | LMNATYMPABCB1STING1ALDH1A1 | |
| SCHEMBL4267744 | 1.00 | LMNA (0.44) | LMNATYMPABCB1STING1ALDH1A1 | |
| SCHEMBL4261195 | 1.00 | LMNA (0.44) | LMNATYMPABCB1STING1ALDH1A1 | |
| SCHEMBL4266270 | 1.00 | LMNA (0.44) | LMNATYMPABCB1STING1ALDH1A1 | |
| SCHEMBL4264220 | 0.96 | LMNA (0.42) | LMNATYMPABCB1STING1ALDH1A1 | |
| SCHEMBL4275608 | 0.96 | LMNA (0.42) | LMNATYMPABCB1STING1ALDH1A1 | |
| SCHEMBL4266764 | 0.96 | LMNA (0.42) | LMNATYMPABCB1STING1ALDH1A1 | |
| SCHEMBL4270329 | 0.96 | LMNA (0.42) | LMNATYMPABCB1STING1ALDH1A1 | |
| SCHEMBL4265607 | 0.96 | LMNA (0.42) | LMNATYMPABCB1STING1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009115893-A2 | NOVEL NUCLEOSIDE DERIVATIVES | HETERO RESEARCH FOUNDATION (IN) | 2009-09-24 | — | — | WO | claimed |
| US-20090233879-A1 | NOVEL NUCLEOSIDE DERIVATIVES | HETERO DRUGS LIMITED (IN) | 2009-09-17 | — | — | US | claimed |
| US-8227431-B2 | Nucleoside derivatives | HETERO DRUGS LIMITED (IN) | 2012-07-24 | — | — | US | disclosed |
| WO-2009115893-A2 | NOVEL NUCLEOSIDE DERIVATIVES | HETERO RESEARCH FOUNDATION (IN) | 2009-09-24 | — | — | WO | disclosed |
| US-20090233879-A1 | NOVEL NUCLEOSIDE DERIVATIVES | HETERO DRUGS LIMITED (IN) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233879-A1 | NOVEL NUCLEOSIDE DERIVATIVES | ENTPD5, PNP, ENTPD1 | LMNA 2060/4885TYMP 4/4885ABCB1 898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.